Search
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalOther chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. … [L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of
Glycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigationalWhen extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin. … [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316] … [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalSimilar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins
Mixtures: IMIPENEM /CILASTATIN KABI POWDER FOR SOLUTION FOR INFUSION 500MG/500MG, IMIPENEM /CILASTATIN Kabi 500 mg/ 500 mg, Powder for solution for infusionCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseVutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows for subcutaneous injections to take place once every three months. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Categories: Antihypertensives for Pulmonary Arterial HypertensionMelphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawn[A230123] The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already. … Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan].
Levomefolic acid
go.drugbank.com/drugs/DB11256ApprovedIt is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. … Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma
Mixtures: Tri-Vi-Flor, Tri-Vi-FlorAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalFor oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label].
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … [A262076] Standard therapy for cTTP involves prophylactic plasma infusions to supplement insufficient ADAMTS13 plasma levels.